Prehospital Ventilator-Associated Pneumonia Prevention Trial
| Status: | Completed |
|---|---|
| Conditions: | Pneumonia, Pneumonia, Hospital, Pulmonary |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases, Other |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 2/7/2015 |
| Start Date: | July 2013 |
| End Date: | August 2014 |
| Contact: | Nicholas M Mohr, MD |
| Email: | nicholas-mohr@uiowa.edu |
| Phone: | 319-353-6360 |
A Pilot Study of Prehospital Oral Chlorhexidine Gluconate to Prevent Early Ventilator Associated Pneumonia in Intubated Trauma Patients
Traumatic injury in rural America is a significant cause of morbidity and mortality, and the
challenges of a rural trauma system can put patients at unique risk. Prolonged transport
times to a trauma center, stopping for care at referring hospitals, and longer exposure to
care-associated factors distinguish rural patients from their urban counterparts.
Ventilator-associated pneumonia (VAP) is a significant risk in rural patients, increasing
hospital stay, healthcare costs, and even mortality in the critically injured. The
investigators propose a pilot study to test the hypothesis that a single dose of oral
chlorhexidine gluconate (antiseptic) for trauma patients in the prehospital environment will
decrease subsequent development of early VAP. Chlorhexidine is currently a standard therapy
in intensive care units to prevent airway colonization and subsequent development of VAP.
Demonstrating safety and effectiveness of prehospital infection control practices could
significantly improve outcomes of traumatic injury in rural America.
challenges of a rural trauma system can put patients at unique risk. Prolonged transport
times to a trauma center, stopping for care at referring hospitals, and longer exposure to
care-associated factors distinguish rural patients from their urban counterparts.
Ventilator-associated pneumonia (VAP) is a significant risk in rural patients, increasing
hospital stay, healthcare costs, and even mortality in the critically injured. The
investigators propose a pilot study to test the hypothesis that a single dose of oral
chlorhexidine gluconate (antiseptic) for trauma patients in the prehospital environment will
decrease subsequent development of early VAP. Chlorhexidine is currently a standard therapy
in intensive care units to prevent airway colonization and subsequent development of VAP.
Demonstrating safety and effectiveness of prehospital infection control practices could
significantly improve outcomes of traumatic injury in rural America.
Inclusion Criteria:
- Adults (age >= 18 years)
- Endotracheal intubation
- Transported by air ambulance
- Traumatic injury
- Interfacility transport (no flights from scene) en route to University of Iowa
Hospitals and Clinics)
Exclusion Criteria:
- Known or suspected pregnancy
- Prisoners
- Patients diagnosed with pneumonia prior to transfer
- Known allergy to chlorhexidine gluconate
- Surgical airway (tracheostomy or cricothyroidotomy)
- Massive aspiration
- Anticipated nonsurvivable injury (survival projected < 24 hours)
We found this trial at
1
site
University of Iowa Hospitals and Clinics University of Iowa Hospitals and Clinics—recognized as one of...
Click here to add this to my saved trials
